Organon & Co (OGN) concluded trading on Thursday at a closing price of $10.07, with 4.4 million shares of worth about $44.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -33.09% during that period and on June 12, 2025 the price saw a loss of about -0.10%. Currently the company’s common shares owned by public are about 259.96M shares, out of which, 258.99M shares are available for trading.
Stock saw a price change of 9.58% in past 5 days and over the past one month there was a price change of 19.31%. Year-to-date (YTD), OGN shares are showing a performance of -32.51% which decreased to -51.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.01 but also hit the highest price of $23.10 during that period. The average intraday trading volume for Organon & Co shares is 5.84 million. The stock is currently trading 8.66% above its 20-day simple moving average (SMA20), while that difference is down -2.49% for SMA50 and it goes to -33.16% lower than SMA200.
Organon & Co (NYSE: OGN) currently have 259.96M outstanding shares and institutions hold larger chunk of about 80.36% of that.
The stock has a current market capitalization of $2.62B and its 3Y-monthly beta is at 0.56. PE ratio of stock for trailing 12 months is 3.49, while it has posted earnings per share of $2.89 in the same period. Its PEG reads 2.93 and has Quick Ratio of 1.15 while making debt-to-equity ratio of 16.52. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 1.38% while standing at 3.18% over the month.
Analysts are in expectations that Organon & Co (OGN) stock would likely to be making an EPS of 0.94 in the current quarter, while forecast for next quarter EPS is 0.94 and it is 4.08 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.9 which is 0.97 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 1.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -6.05% while it is estimated to increase by 5.76% in next year. EPS is likely to grow at an annualized rate of 1.19% for next 5-years, compared to annual growth of -23.49% made by the stock over the past 5-years.
Coverage by JP Morgan stated Organon & Co (OGN) stock as an Underweight in their note to investors on September 06, 2024, suggesting a price target of $20 for the stock. On November 03, 2023, Goldman Downgrade their recommendations, while on September 21, 2023, Barclays Initiated their ratings for the stock with a price target of $28. Stock get an Outperform rating from Raymond James on March 16, 2023.
